Open AccessEfficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
Author(s) -
Kutsch Nadine,
Pallasch Christian,
Decker Thomas,
Hebart Holger,
Chow Kai Uwe,
Graeven Ullrich,
Kisro Jens,
Kroeber Alexander,
Tausch Eugen,
Fischer Kirsten,
Fink AnnaMaria,
Wendtner ClemensMartin,
Ritgen Matthias,
Stilgenbauer Stephan,
Zhang Danjie,
Li Biao,
Jürgensmeier Juliane M.,
Rajakumaraswamy Nishanthan,
Bhargava Pankaj,
Hallek Michael,
Eichhorst Barbara
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000729
Subject(s) - idelalisib , medicine , obinutuzumab , chemoimmunotherapy , ibrutinib , chronic lymphocytic leukemia , adverse effect , rituximab , ofatumumab , bruton's tyrosine kinase , oncology , ighv@ , population , leukemia , gastroenterology , tyrosine kinase , lymphoma , receptor , environmental health